Be a part of the solution!
Dr. Michael Tuchman
Join Michael Tuchman, MD, Rhonda Skiles, ARNP and staff as we evaluate potentially new and improved options in research for Mild Cognitive Impairment and Alzheimer’s disease.
[imedica_feature_boxes title=”Disorders and Symptoms” style=”Style3″ box_min_height=”150″ border_width=”” bgcolor=”#1e73be” back_hover_color=”#1e73be” titlecolor=”#ffffff” titlehover_color=”#ffffff” descriptioncolor=”#ffffff” bdescription_hover_color=”#ffffff” title_font_size=”” title_line_ht=”” desc_font_size=”” desc_line_ht=”” fold_bg_color=”#0067a3″]Have you suffered with memory problems for at least a year? You may have Mild Cognitive Impairment
[imedica_feature_boxes title=”Research Studies” style=”Style3″ border_width=”” bgcolor=”#1e73be” back_hover_color=”#1e73be” titlecolor=”#ffffff” titlehover_color=”#ffffff” descriptioncolor=”#ffffff” bdescription_hover_color=”#ffffff” title_font_size=”” title_line_ht=”” desc_font_size=”” desc_line_ht=”” fold_bg_color=”#0067a3″]If you have been diagnosed with mild to moderate Alzheimer’s Disease, you may qualify for a research study
[imedica_feature_boxes style=”Style3″ border_width=”” bgcolor=”#1e73be” back_hover_color=”#1e73be” titlecolor=”#ffffff” titlehover_color=”#ffffff” descriptioncolor=”#ffffff” bdescription_hover_color=”#ffffff” title_font_size=”” title_line_ht=”” desc_font_size=”” desc_line_ht=”” fold_bg_color=”#0067a3″ margin_design_tab_text=””]
Give us a call
561-282-5546
[imedica_ititle title=”Are You Eligible”][contact-form-7 404 "Not Found"]
MILD COGNITIVE IMPAIRMENT
Having Memory Problems? Trouble Thinking Clearly?
If you are concerned about changes in you or your loved one’s memory, call our research department at (561) 282-5546.
Some of the signs of Mild Cognitive Impairment:
- Difficulty finding the words
- Problems with thinking and memory
- Trouble remembering appointments
- Repeating questions or stories over and over
- Forgetting details of conversations
Alzheimer’s Disease
Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with Donepezil. This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient ) once daily by mouth. Potential patients must have been receiving a drug containing Donepezil for the last 6 months, at a dose of 10-mg per day for the last 4 months.
Criteria:
- Diagnosed with mild to moderate Alzheimer’s Disease.
- Age 50 or older
- Have a caregiver to join you during every visit
- You do not have any other conditions affecting your mental ability. e.g. schizophrenia, Parkinson’s disease
- If you are taking certain drugs, you will not be ale to join the study. You will be asked about your medication history by the study doctor if you decide to get involved.
Why join the STARBEAM STUDY?
- You might be able to help with a clinical research study looking at a potential new treatment for mild to moderate Alzheimer’s disease.
- You will receive the best standard of study-related medical care.
- You may receive and investigational treatment, designed to help improve memory, thinking and reasoning.
- All study-related medications and consultations during the study will be free of charge and reasonable travel, parking and food expenses will be paid